MicroQuin is published in Nature Oncogene
MicroQuin's research is published in Nature Oncogene showing how our therapeutic can treat not only cancer but traumatic brain injury, viral infection and wound healing. Best part - our drugs do NOT induce any toxicity in normal cells.
Want to understand more:
Nov 2024
MicroQuin has a feature article written about it in Upward Magazine from the International Space Station
Article title: Orbital Oncology: 3D Cell Cultures in Space Reveal the Secret to Killing Cancer Cells on Earth
The article describes how MicroQuin's revolutionary tehcnology was discovered using work performed on the ISS and using funding from CASIS and Boeing as part of the Technology in Space awards from MassChallenge
Image:
National Aeronautics and Space Administration astronaut Christina Koch working on MicroQuin's protein crystallization research on the ISS.
Media Credit: NASA
Oct 2024
MicroQuin Wins DoD Grant for the development of Traumatic Brain Injury Therapeutics
MicroQuin was awarded a $1 million grant from the Department of Defense (DoD) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) managed by the office of Congressionally Directed Medical Research Programs.
Aug 2023
MicroQuin Wins DoD Grant for the development of Lung Cancer Therapeutics
MicroQuin was awarded a $350k grant from the Department of Defense (DoD) Lung Cancer Research Program (LCRP) managed by the office of Congressionally Directed Medical Research Programs.
Mar 2023
Sep 2022
MicroQuin Wins DoD Grant for the development of Lung Cancer Therapeutics
MicroQuin was awarded a $100k grant from the Department of Defense (DoD) Lung Cancer Research Program (LCRP) managed by the office of Congressionally Directed Medical Research Programs.
MicroQuin Wins DoD Grant for the development of Rare Cancer Therapeutics
MicroQuin was awarded a $100k grant from the Department of Defense (DoD) Rare Cancer Research Program (RCRP) managed by the office of Congressionally Directed Medical Research Programs.
Apr 2022
The ISS National Lab’s MicroQuin 3D Tumor examines the effects of a drug on breast and prostate cancer cells in space.
Feb 2022
Jan 2022
MicroQuin Wins DoD Grant for the Development of Ovarian Cancer Therapeutics
MicroQuin was awarded a $250k grant from the Department of Defense (DoD) Ovarian Cancer Research Program (OCRP) managed by the office of Congressionally Directed Medical Research Programs.
AUG 2021
MicroQuin Signs Non-Clincal Evaluation Agreement NIH/NIAID
MicroQuin Announces Preclincial Collaboration with NIAID to Evaluate MicroQuin Therapeutics for the treatment of viral infections.
JUN 2021
MicroQuin's experiments performed aboard the International Space Station have implications for earthbound biopharma development.
JAN 2021
Tellus Bioventures invests in MicroQuin
MicroQuin received investments from Tellus Bioventures. Tellus BioVentures is a biotechnology investment fund focused on early-stage innovation and company formation.
APR 2020
MicroQuin wins second place at South Summit Competition
South Summit is the leading innovation platform bringing together the most innovative startups regardless their industry, development stage and country.
MAR 2019
MicroQuin and Dr. Scott Robinson featured in Boston Globe
A glimpse into the journey that Dr. Robinson has been on to drive our technology to its current stage.
Nov 2018
MicroQuin joins prestigious LabCentral in Kendall Square, Cambridge
MicroQuin has been accepted into the highly competitive Lab Central. We intend to continue our ground breaking research at this facility and strive to make significant advances in delivering first-in-class treatments for breast cancer. Watch this space!
Oct 2018
MicroQuin is going to space for studies in the International Space Station!
MicroQuin wins TWO grants from CASIS/BOEING under this year’s “Technology in Space” program. For the first time CASIS funded 2 projects from one company as part of its MassChallenge competition. These studies will be performed on the ISS and the data will have considerable impact on creating new scientific approaches to battling cancer.
Sep 2018
MicroQuin was invited to present its ground-breaking technologies
MicroQuin was invited to showcase our high impact and transformational technology at Health Pioneers 2018. The conference brings together decision-makers and innovators from the pharma, biotech, insurance and public health sectors to explore new ways to collaborate and pioneer.
Sep 2018
MicroQuin is a winner of the Health Hub Vienna 2018 package
Health Hub Vienna is an acceleration program is managed by INiTS, Vienna’s high-tech incubator with an over 15-year track record of successfully developing start-ups in the life sciences.
Sep 2018
MicroQuin is a Top 26 Finalist of MassChallenge
The 26 finalists were selected among the 128 early-stage ventures at MassChallenge Boston’s acceleration program in May. The selected companies will move into the final judging round of the MassChallenge Awards, where they’ll compete for shares of $1.5 million in equity-free prizes.